UCB, a leading global biopharmaceutical company, has announced the publication of results from the Phase 3 BE HEARD I and BE HEARD II trials in The Lancet. These trials evaluated the effectiveness and safety of bimekizumab, an inhibitor of IL-17A…
A global oncology company today announced the presentation of new analyses for BRUKINSA® (zanubrutinib) at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 31 to June 4, 2024. These presentations underscore the efficacy and safety…
Today, Astellas announced the signing of a memorandum of understanding with YASKAWA Electric Corporation (YASKAWA), marking the beginning of discussions toward creating an innovative cell therapy ecosystem. This collaboration aims to merge pharmaceutical and robotics technologies, potentially revolutionizing cell therapy…
AstraZeneca to Establish $1.5 Billion Antibody Drug Conjugates (ADCs) Manufacturing Facility in Singapore AstraZeneca plans to build a $1.5 billion manufacturing facility in Singapore, aimed at enhancing the global supply of its Antibody Drug Conjugates (ADCs). ADCs represent next-generation cancer…
Roche announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with palbociclib (Ibrance®) and fulvestrant. This treatment is for adult patients with PIK3CA-mutated, hormone receptor-positive, human…
RVL Pharmaceuticals has proudly announced that Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, its prescription eye drop, has received the esteemed 2024 Shape Skin Award from Shape Magazine. This prestigious recognition, naming Upneeq® as “Best for Lift” in the professional category,…
AbbVie (NYSE: ABBV) announced it will present 15 abstracts at the 2024 Digestive Disease Week (DDW) Annual Meeting, occurring May 18-21 in Washington, D.C., and virtually. “At DDW, AbbVie is presenting research demonstrating rapid symptom relief and notable improvements in…
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials for once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes. These trials included both insulin-naïve patients and those requiring…
SunLink Health Systems, Inc. (NYSE American: SSY) disclosed today a loss from continuing operations of $824,000 (equating to a loss of $0.12 per fully diluted share) for its third fiscal quarter concluding on March 31, 2024. This contrasts with a…
OmniAb has announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit, held at the Omni Hotel. Earlier today, the company presented an overview of xPloration, a high-throughput single B-cell screening platform enhanced…
Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders such as complement-mediated diseases, cancers, and addictive and compulsive disorders, has reported…
VBI Vaccines Inc. (Nasdaq: VBIV) Announces Q1 2024 Business Update and Financial Results VBI Vaccines Inc. (Nasdaq: VBIV), a biopharmaceutical company focused on immunology to develop potent disease prevention and treatment solutions, today released a business update and financial results…
